SciSparc Ltd. (SPRC)
NASDAQ (CM) NASDAQ (CM) Primary 
SET Summary
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?
On Monday, SciSparc Ltd SPRC stock is trading higher with a session volume of 30.86 million compared to an average volume of 7.73 million as per data from Benzinga Pro.
S&P 500 Edges Lower, SciSparc Shares Surge
U.S. stocks traded slightly lower toward the end of trading, with the S&P 500 edging lower on Thursday.
Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy
Friday, SciSparc Ltd. SPRC signed an exclusive patent license agreement with Polyrizon Ltd to out-license its SCI-160 program to treat pain.
SciSparc Ltd. (SPRC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has SciSparc Ltd. ever had a stock split?
SciSparc Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Oz Adler CEO | NASDAQ (CM) Exchange | M82618121 CUSIP |
| IL Country | 2 Employees | - Last Dividend | 3 Jul 2025 Last Split | 30 Aug 2021 IPO Date |
Overview
SciSparc Ltd. is a clinical-stage pharmaceutical company focused on the development of drugs derived from cannabinoid therapies. The company has branched out into exploring the therapeutic potentials of cannabinoids across various medical conditions, including Tourette syndrome, Alzheimer's disease, pain, autism spectrum disorder, and status epilepticus. With a rebranding from Therapix Biosciences Ltd. to SciSparc Ltd. in January 2021, it underscores its commitment to advancing scientific discoveries in cannabinoid research. Founded in 2004 and positioned in Tel Aviv-Yafo, Israel, SciSparc collaborates with other organizations like Procaps, The Israeli Medical Center for Alzheimer's, and Clearmind Medicine Inc., aiming to bolster its drug development pipeline and enhance its contributions to pharmaceuticals and healthcare.
Products and Services
-
SCI-110
Designed as a therapeutic agent, SCI-110 targets conditions such as Tourette syndrome and Alzheimer's disease, focusing also on agitation associated with Alzheimer's. SciSparc's development of SCI-110 represents its dedication to addressing neurological conditions. The company furthers this commitment through a partnership with Procaps for the development and commercial manufacturing, alongside collaboration with The Israeli Medical Center for Alzheimer's to execute a phase IIa clinical trial. This trial aims to evaluate SCI-110's safety, tolerability, and effectiveness in patients experiencing agitation due to Alzheimer's disease.
-
SCI-160
SCI-160 is under development for the treatment of pain. This indicates SciSparc's venture into managing chronic conditions that affect a significant portion of the global population. The endeavor to develop SCI-160 showcases the company's ambition to offer new pain management solutions derived from cannabinoid research.
-
SCI-210
Focused on addressing autism spectrum disorder and status epilepticus, SCI-210 represents SciSparc's multidimensional approach to leveraging cannabinoids for neurological disorders. This development effort underscores the company's recognition of the unmet medical needs within these conditions and its pursuit to fill these gaps with innovative treatments.
-
CannAmide
CannAmide is being developed as an anti-inflammatory and chronic pain solution. This product, consisting of a palmitoylethanolamide oral tablet in a softgel capsule form, is another example of SciSparc's commitment to exploring the therapeutic potentials of cannabinoids. The company's agreement with Procaps for the development and commercial manufacturing of CannAmide signifies strides towards providing relief for chronic pain and inflammation through novel modalities.
Contact Information
